Wanbury Gets EU Approval for Rivaroxaban API, Receives USFDA DMF Clearances
Wanbury Limited has announced two important regulatory developments that could strengthen its pharmaceutical API business.
The company has received European Directorate for the Quality of Medicines and Healthcare (EDQM) approval for Rivaroxaban API. Wanbury has also received USFDA DMF clearances for Paroxetine HCl and Metformin HCl.
The company announced on August 13, 2026, through a regulatory filing under Regulation 30 of the SEBI LODR Regulations.
Wanbury Regulatory Update: Key Highlights
- EDQM approval received for Rivaroxaban API.
- Approval will help Wanbury cater to customers in the European Union and other CEP-accepting markets.
- USFDA DMF clearance received for Paroxetine HCl.
- USFDA DMF clearance received for Metformin HCl.
- ANDA reviews are ongoing for multiple customers.
- The developments could expand Wanbury’s API business and customer opportunities.
EDQM Approval for Rivaroxaban API
Wanbury has received approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product, Rivaroxaban API.
The approval is significant because it enables the company to meet customer requirements in the EU and other countries that accept CEPs.
Rivaroxaban is an API used in pharmaceutical formulations, and regulatory approval in European markets can support opportunities with customers operating in these regions.
New Product Adds to Wanbury’s API Portfolio
The approval represents the addition of Rivaroxaban API to Wanbury’s portfolio of products.
Regulatory approvals are an important part of the API business because they allow manufacturers to supply products to regulated pharmaceutical markets.
For Wanbury, the EDQM approval could therefore provide access to additional customer opportunities in Europe and other CEP-accepting countries.
USFDA DMF Clearance for Paroxetine HCl
Along with the European approval, Wanbury has received DMF clearance from the US Food and Drug Administration (USFDA) for Paroxetine HCl.
A Drug Master File, or DMF, contains detailed information about facilities, processes, materials and other aspects related to the manufacture of pharmaceutical substances.
The clearance provides regulatory support for Wanbury’s ability to supply the API to customers requiring US regulatory compliance.
USFDA DMF Clearance for Metformin HCl
Wanbury has also received USFDA DMF clearance for Metformin HCl.
Metformin is a widely used pharmaceutical ingredient, and the clearance strengthens Wanbury’s regulatory position for this product in the US market.
Together, the two USFDA clearances add further regulatory support to the company’s API business.
ANDA Reviews Underway
The company also stated that ANDA reviews are underway for multiple customers.
Abbreviated New Drug Applications, or ANDAs, are part of the US regulatory pathway for generic pharmaceutical products.
The ongoing reviews could potentially create additional opportunities for Wanbury if the relevant applications receive regulatory approval and lead to commercialisation.
However, the company has not provided details in the announcement regarding the specific customers, products or potential revenue associated with these ongoing reviews.
Why the Approvals Matter for Wanbury
The latest regulatory developments could support Wanbury’s efforts to expand its presence in regulated pharmaceutical markets.
The combination of:
- Rivaroxaban API approval from EDQM
- Paroxetine HCl USFDA DMF clearance
- Metformin HCl USFDA DMF clearance
- Ongoing ANDA reviews
provides multiple regulatory developments for the company.
These approvals could help Wanbury pursue additional customers in Europe, the US and other regulated markets.
Potential Growth Opportunity
For pharmaceutical API manufacturers, regulatory approvals can create opportunities to enter new markets and supply additional customers.
Wanbury’s latest approvals could therefore support its API business by increasing the number of markets and customers it can potentially serve.
The actual financial impact, however, will depend on customer approvals, commercial agreements, product volumes and eventual sales.
The company has not disclosed specific order values or revenue projections related to these regulatory approvals in the August 13 announcement.